Immobilized subjects.
Conditions
Interventions
Product Name: Allopurinol
Pharmaceutical Form: Tablet
CAS Number: 315-30-0
Other descriptive name: ALLOPURINOL
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Sponsors
Instituo de Investigacion Sanitaria La Fe
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients with grade II sprain. Males. Ages 20 to 40 years. Patients not taking regular medication. The concept is understood not to take regular medication to all patients who chronically fail to take any medication in a timely manner regardless of whether they needed to take the last week or last month for a condition treatment on time. All patients must have written full informed consent specifically for this study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Liver and gastrointestinal disease. Hipotiroismo untreated. Alcohol and / or substance abuse. Vitamin supplements. Eating disorders. Drugs that lower lipid levels. Hypotensive drugs. Smokers. Athletes who perform strenuous exercise. Mental disorders, depression or anxiety intensity. These diseases cause the patient unable to understand the nature or scope and possible consequences of the study. Patients with any infectious process and / or inflammatory before collecting the sample. Patients may not follow the protocol because of its lack of cooperation, inability to return to subsequent visits and there is little chance of completing the study procedures. Hypersensitivity to allopurinol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Determining the effect of allopurinol administration on the prevention of loss of muscle mass in immobilized subjects. In this way we aim to determine the role of xanthine oxidase in free radical production in skeletal muscle during a period of immobilization;Secondary Objective: To determine the effect of allopurinol administration on the size of the muscles of the leg in a group of subjects immobilized for a period of 15 days. To determine the effect of allopurinol administration on the loss of muscle strength of leg muscles in a group of subjects immobilized for a period of 15 days. To determine the effect of allopurinol administration on various parameters of systemic oxidative stress (GSH, GSSG, MDA and oxidized proteins) and plasma activity of xanthine oxidase, after a period of immobilization of 15 days;Primary end point(s): To determine the role of xanthine oxidase in free radical production in skeletal muscle during a period of immobilization.;Timepoint(s) of evaluation of this end point: During a period of immobilization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Determinar el efecto de la administración de alopurinol sobre el tamaño de la musculatura de la pierna en un grupo de sujetos inmovilizados durante un periodo de 15 días. Determinar el efecto de la administración de alopurinol sobre la pérdida de fuerza muscular de la musculatura de la pierna en un grupo de sujetos inmovilizados durante un periodo de 15 días. Determinar el efecto de la administración de alopurinol sobre distintos parámetros de estrés oxidativo sistémico (GSH, GSSG, MDA y proteínas oxidadas), así como la actividad plasmática de la xantina oxidasa, tras un periodo de inmovilización de 15 días de duración.;Timepoint(s) of evaluation of this end point: For a period of 15 days. | — |
Countries
Spain
Contacts
Public ContactUREC
Instituto de Investigacion Sanitaria La Fe
Outcome results
None listed